A Phase I Dose Escalation Study of Oral MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2014
At a glance
- Drugs MK 2206 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 06 Mar 2012 Actual patient number changd from 72 to 104 according to ClinicalTrials.gov.
- 09 Feb 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 09 Aug 2011 Planned End Date changed from 1 Aug 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.